Direct Antiglobulin Test (Newborn): Nursing Guide
The newborn direct antiglobulin test (DAT), also called the direct Coombs test, detects maternal antibodies attached to an infant’s red blood cells — a key clue in isoimmune hemolysis when jaundice appears early or bilirubin rises rapidly. Nurses ensure DAT and infant blood typing are obtained promptly when the maternal antibody screen is positive or unknown, communicate results with bilirubin trends, and escalate when a positive DAT signals heightened hemolysis and hyperbilirubinemia risk.
Contents
Quick Facts
Key Takeaway
A positive newborn DAT means antibodies are coating the infant’s red cells and immune-mediated hemolysis is likely — but a negative DAT does not rule out every hemolytic cause.
Specimen & Collection Details
Nurse quick-reference for collection prep that affects result quality.
EDTA (lavender-top) or blood-bank tube per institutional neonatal transfusion protocol
Tube type and additive are Turnaround and screening rules vary by institution; follow local institutional policy as a single universal standard — follow the reporting blood bank or laboratory collection guide
Newborn cord blood or peripheral venous/capillary blood (EDTA or per blood-bank protocol)
Small-volume cord or capillary/venous sample per institutional neonatal blood-bank protocol
As soon as possible after birth when maternal antibody screen is positive or unknown; cord blood at delivery is preferred when feasible per AAP 2022 hyperbilirubinemia guidance
No special preparation is usually required, but nurses should follow local policy and the ordering clinician’s instructions
Label with infant identifiers, date, time, and specimen source (cord vs peripheral); transport to blood bank or laboratory per institutional policy without delay
Varies by site — often same shift when cord blood is sent at birth; longer if peripheral sample is required after a missed cord collection
Neonatal blood bank / transfusion medicine / nursery laboratory
What is Direct Antiglobulin Test (Newborn)?
Direct Antiglobulin Test (Newborn) is a qualitative blood-bank test that detects antibodies (most often maternal IgG) already bound to a newborn’s red blood cells. It is also called the direct Coombs test or direct antiglobulin test (DAT). A positive result supports antibody-mediated hemolysis — commonly related to ABO or Rh incompatibility — and helps clinicians decide how intensively to monitor jaundice, bilirubin, and anemia.
Overview
Nurses in labor and delivery, newborn nurseries, and postpartum units coordinate DAT when infants are at risk for hemolytic disease of the newborn. The 2022 American Academy of Pediatrics (AAP) clinical practice guideline states that if the maternal antibody screen is positive or unknown because prenatal screening was not performed, the infant should have a DAT and blood type determined as soon as possible using cord or peripheral blood.
standard clinical references and neonatal transfusion references describe DAT as part of the workup when jaundice or anemia suggests red cell destruction. Nurses do not diagnose isoimmune hemolysis at the bedside, but they prevent harm by ensuring timely specimen collection, documenting maternal blood type and antibody screen results, trending newborn bilirubin with age in hours, and arranging CBC and reticulocyte testing per orders when hemolysis is suspected.
Before collection, confirm whether cord blood was obtained at delivery, maternal blood type and antibody screen status, infant blood type when available, and visible jaundice assessment findings. After results, communicate positive DAT with bilirubin zone on the unit nomogram, feeding and weight trends, and whether the birthing parent received Rh(D) immune globulin during pregnancy — which can cause a positive DAT without active hemolysis per AAP guidance. Escalate early jaundice, rapid bilirubin rise, pallor, or anemia signs according to facility policy.
Isoimmune Hemolysis and DAT Escalation Safety
A missed or delayed newborn DAT when the maternal antibody screen is positive or unknown can postpone recognition of isoimmune hemolysis — just when bilirubin may rise fastest. Nurses protect infants by ensuring cord blood type and DAT are obtained at delivery when ordered, escalating early jaundice even before results return, and never treating a positive DAT as a stand-alone diagnosis without bilirubin trends and blood bank input.
- Positive DAT with bilirubin crossing or approaching phototherapy threshold in the first days of life
- Maternal antibody screen positive but no cord or peripheral DAT within expected timeframe
- Early jaundice (within 24 hours) with rising bilirubin while DAT is pending
- Assuming negative DAT rules out hemolysis when bilirubin rise and pallor continue
Document: maternal and infant blood types, antibody screen status, DAT result and specimen source, bilirubin with age in hours, CBC/reticulocyte trends, prescriber and blood bank notification, phototherapy orders, and parent teaching.
What Newborn DAT Can and Cannot Tell You
This test can help identify:
- Antibody coating on infant red cells supporting antibody-mediated hemolysis
- Increased hyperbilirubinemia neurotoxicity risk when DAT is positive per AAP risk factors
- Need for intensified bilirubin monitoring and blood bank coordination
- Isoimmune hemolytic disease context when paired with maternal antibody screen and blood types
This test cannot:
- Identify the specific maternal antibody without blood bank reflex testing
- Replace serial bilirubin measurement on age-in-hours nomograms
- Exclude non-immune hemolysis or all causes of jaundice when negative
- Determine transfusion or phototherapy thresholds without prescriber interpretation
Pre-collection Checks for Cord and Peripheral DAT
Verify
Clarify before proceeding when:
- Maternal antibody screen is positive but cord DAT was not collected at birth
- Infant identifiers on cord specimen do not match wristband
- Jaundice appears within 24 hours before DAT result is available
- Positive DAT is present but bilirubin monitoring orders are missing
- Parents received Rh immune globulin — clarify interpretation pathway with prescriber
- Blood bank reports specimen inadequate or hemolyzed — repeat collection needed
- Clinical pallor or poor feeding conflicts with “negative DAT” reassurance
Reading DAT With Maternal Antibody Screen and Bilirubin
Integrate DAT with maternal antibody screen, infant and maternal blood types, bilirubin trend on hour-specific nomograms, CBC, reticulocytes, feeding, and exam. A positive DAT raises surveillance intensity; a negative DAT does not end the jaundice workup when timing or trends remain concerning.
| Clinical context | Pair with DAT | Nursing focus |
|---|---|---|
| Maternal screen positive, cord DAT pending | Early jaundice at 16 h | Obtain peripheral DAT if cord missed; expedite bilirubin; notify prescriber |
| Type O mother, type A infant, DAT positive | TSB rising toward phototherapy line | Intensify bilirubin schedule; support feeding; blood bank awareness |
| DAT positive after maternal anti-D IG | TSB below treatment threshold | Clarify interpretation with prescriber; continue monitoring per AAP risk guidance |
| DAT negative | Rapid bilirubin rise and pallor | Escalate expanded hemolysis workup; do not dismiss non-immune causes |
Reference ranges and critical values may vary by laboratory, institution, analyzer, age, sex, pregnancy status, and clinical context. Always interpret results using the reporting laboratory’s reference range and local escalation policy.
DAT Cord Blood and Jaundice Timing at the Bedside
| Bedside point | Nursing note |
|---|---|
| Cord first | High-risk births — confirm cord type/DAT sent before mother leaves L&D |
| Screen trigger | Positive or unknown maternal antibody screen = infant DAT ASAP per AAP |
| DAT ≠ treatment | Positive DAT prompts monitoring intensity; phototherapy follows bilirubin thresholds |
| Anti-D IG effect | Document maternal Rh immune globulin — may alter DAT clinical meaning |
| Early jaundice | Do not wait for DAT to act when jaundice appears in first 24 hours |
| Blood bank loop | Call blood bank when DAT positive and transfusion planning is possible |
DAT in Newborn Hemolysis Screening Workflow
Diagnostic safety badge: Critical-result test — prompt review and escalation may be required when DAT is positive with rising bilirubin or early jaundice.
Check-before-test protocol
- Maternal type, Rh(D), antibody screen on admission
- Cord blood type/DAT at delivery when high-risk
- Peripheral DAT if cord collection missed
- Link DAT to bilirubin, CBC, and reticulocytes
- Notify prescriber and blood bank when DAT positive
Critical teach-back questions
- “Can you tell me why we tested your baby’s blood for antibodies on the red cells?”
- “What changes in skin color, feeding, or alertness should you report right away?”
- “How often will bilirubin be rechecked while we watch for jaundice?”
Care coordination: neonatology, pediatrics, blood bank, laboratory, lactation, and outpatient follow-up clinic — per institutional protocol.
Newborn DAT Quick Clinical Checklist
- Is the maternal antibody screen positive or unknown?
- Was cord blood sent for infant type and DAT at delivery when indicated?
- What are maternal and infant blood types and the DAT result?
- How is bilirubin trending with age in hours on the unit nomogram?
- Has the prescriber and blood bank been notified when DAT is positive?
Why Direct Antiglobulin Test (Newborn) is Ordered
Newborn DAT is ordered to detect isoimmune hemolysis risk and guide intensive hyperbilirubinemia monitoring.
| Clinical Indication | What the Test Answers | Nursing Rationale |
|---|---|---|
| Maternal antibody screen positive at admission or prenatal labs | Are maternal antibodies present that could coat infant red cells? | AAP Key Action Statement recommends infant DAT and blood typing as soon as possible when the maternal antibody screen is positive. |
| Maternal antibody screen unknown (no prenatal screening documented) | Was prenatal antibody screening missed or unavailable? | Unknown maternal antibody status triggers the same urgent infant DAT and blood type requirement per AAP 2022 guidance. |
| Early jaundice or rapidly rising bilirubin with hemolysis concern | Could antibody-mediated hemolysis be driving hyperbilirubinemia? | standard clinical references lists Coombs testing among jaundice workup tests; DAT supports hemolysis pathway when clinical timing and trends are concerning. |
| Known ABO or Rh incompatibility risk (e.g., type O mother, Rh-negative mother) | Is there a recognized maternal–fetal blood group mismatch? | Rh and ABO incompatibility are common DAT-related pathways; nurses ensure specimens are not delayed when risk is identified before or after birth. |
Contraindications and Precautions
There are no absolute contraindications to newborn blood sampling for DAT. Nursing focus is on correct timing, labeling, and minimizing unnecessary repeat heelsticks when cord blood could have been collected at delivery.
- Positive DAT with jaundice in the first 24 hours or bilirubin crossing phototherapy threshold on age-in-hours nomogram
- Rapid bilirubin rise, pallor, poor feeding, or lethargy with positive or pending DAT while hemolysis workup is incomplete
- Missed cord DAT when maternal antibody screen was positive — obtain STAT peripheral sample and notify blood bank and prescriber
- Positive DAT after maternal Rh(D) immune globulin in pregnancy may not indicate active hemolysis — prescriber interprets per AAP neurotoxicity risk factor guidance
- Negative DAT does not exclude non-immune hemolysis (e.g., G6PD deficiency) or all causes of jaundice per neonatal references
- ABO incompatibility may yield weaker DAT reactions — do not reassure solely because jaundice appears mild on first exam
- Positive DAT with bilirubin approaching or crossing phototherapy threshold for age and risk profile
- Hemoglobin drop, rising reticulocytes, or clinical anemia signs with positive DAT
- DAT still pending while infant has early jaundice and orders for phototherapy are being considered
Patient Preparation
Newborns require no fasting for DAT. Preparation centers on maternal–infant blood bank data, cord blood planning, and parent communication.
Pre-test checksDocument whether the birthing parent received Rh(D) immune globulin during pregnancy — this may affect DAT interpretation per AAP guidance. Review infant medications that may cause hemolysis only when ordered or listed in institutional protocols; do not hold feeding unless specifically ordered.
Performance — nursing procedure guide
This page is a Tests & Diagnostics guide for Direct Antiglobulin Test (Newborn). It emphasizes why the test is ordered, how to interpret results, when to escalate, and preparation factors that affect validity — not step-by-step performance technique (those live under Nursing Procedures when available).
Step-by-step technique, supplies, infection prevention, and immediate post-procedure monitoring for this test are covered in:
Use the Patient preparation, Results and interpretation, and Nursing responsibilities sections on this page for order verification, pre-analytic checks, result follow-up, critical-value escalation, and documentation.
Result follow-up at a glance
Nursing workflow on this page — from order to safe action on results:
Results and Interpretation
DAT is reported qualitatively as positive or negative (terminology may vary by laboratory). Interpret each result with maternal antibody screen, infant and maternal blood types, bilirubin trend, CBC, reticulocyte count, and clinical exam — not in isolation.
Reference ranges, critical values, and protocols may vary by laboratory, institution, patient population, and testing method. Always follow local policy and the reporting laboratory’s reference range.
| Result | Range / Finding | Clinical Meaning | Nursing Action |
|---|---|---|---|
| Negative / not detected | Negative / not detected (laboratory-specific wording) | No antibodies detected on infant red cells by the performing method — lower isoimmune hemolysis concern when maternal antibody screen is negative and clinical picture fits | Continue routine newborn jaundice screening per AAP and unit protocol; do not skip bilirubin measurement because DAT is negative |
| Equivocal / borderline | Weak-positive or equivocal reporting (when laboratory provides this category) | May reflect low-level sensitization — requires blood bank and prescriber interpretation with repeat testing or adjunct assays per institutional policy | Notify blood bank and prescriber; trend bilirubin and hemoglobin; avoid false reassurance |
| Positive / elevated | Positive / detected | Antibodies coating infant red cells — supports antibody-mediated hemolysis and increased hyperbilirubinemia neurotoxicity risk unless Rh immune globulin effect alone per AAP | Notify prescriber and blood bank; intensify bilirubin monitoring; coordinate phototherapy and adjunct labs per protocol |
| Not applicable / below detection limit | Not applicable for qualitative DAT reporting | Low or absent detection is not reported as a numeric low value — focus on negative vs positive | Continue clinical monitoring; pursue non-immune causes of jaundice if presentation worsens |
Critical Results and Escalation
Institution-wide numeric critical DAT values are Turnaround and screening rules vary by institution; follow local institutional policy. Escalation is clinical: positive DAT with rapidly rising bilirubin, early jaundice, anemia, or neurotoxicity signs requires urgent prescriber and neonatology coordination per AAP hyperbilirubinemia guidance.
| Critical Finding | Threshold / Value | Immediate Action |
|---|---|---|
| Positive DAT with bilirubin at phototherapy threshold | Positive DAT and TSB at or above phototherapy line for age in hours and risk category | Notify prescriber immediately; initiate phototherapy per orders; repeat bilirubin per nomogram; document neurotoxicity risk factors |
| Positive DAT with suspected acute bilirubin encephalopathy | Positive DAT plus lethargy, poor suck, high-pitched cry, or arching with elevated bilirubin | Activate local emergency response according to institutional protocol; urgent neonatology evaluation |
| High-risk infant without DAT when maternal screen positive | Maternal antibody screen positive but no cord or peripheral DAT resulted within expected timeframe | Obtain STAT peripheral sample; notify blood bank and prescriber; document delay reason and communication |
Escalate according to facility policy and the patient’s clinical condition when DAT is positive with concerning bilirubin trends, when early jaundice develops before results return, when anemia signs appear, or when a required DAT was not collected at birth.
Factors Affecting Results
DAT interpretation depends on maternal antibody identity, infant blood group, specimen source, laboratory method, and whether Rh immune globulin was given during pregnancy.
- Positive DAT from passive anti-D after maternal Rh(D) immune globulin without active hemolysis
- Assuming any positive DAT always requires exchange transfusion without bilirubin and exam context
- Labeling weak ABO reactions as clinically insignificant without prescriber and blood bank review
- Negative DAT while bilirubin rises rapidly — consider non-immune hemolysis and expanded workup
- Reassurance based on negative DAT when jaundice appears in the first 24 hours
- Delayed or hemolyzed specimen interpreted as negative without repeat collection
- Cord blood not obtained when high-risk — peripheral delay prolongs turnaround
- Specimen mislabeling or wrong patient identifiers
- Maternal Rh immune globulin administration affecting DAT interpretation
DAT detects antibodies on infant red cells but does not identify every hemolytic mechanism. It does not replace bilirubin monitoring, blood typing, maternal antibody identification, or clinical assessment. Negative DAT does not exclude G6PD deficiency, sepsis, or collection problems. Always interpret with bilirubin trends, CBC, reticulocytes, and exam.
Nursing Responsibilities
Nursing care spans antenatal risk identification, cord blood coordination at delivery, peripheral collection when needed, result communication, and hyperbilirubinemia surveillance.
Before the TestDocumentation
Clear documentation supports blood bank, nursery, and neonatology handoffs.
“18-hour-old, 39w1d GA. Maternal type O Rh+; antibody screen negative. Infant type A Rh+. Cord DAT positive at birth; repeat peripheral DAT positive. TSB 11.2 mg/dL at 18 h — approaching phototherapy zone. Hgb 14.1 g/dL; reticulocytes pending. Dr. Chen notified; intensified bilirubin schedule ordered. Parents taught poor feeding and worsening jaundice signs. Blood bank aware for potential transfusion planning.”
- Maternal blood type, Rh(D), and antibody screen status
- Infant blood type, DAT result, specimen source (cord vs peripheral), and time
- Bilirubin values with age in hours and nomogram interpretation
- CBC/reticulocyte trends and phototherapy orders when applicable
- Prescriber and blood bank notification with read-back per policy
- Parent teaching on jaundice progression and follow-up appointments
Patient and Family Education
Use plain language with parents while emphasizing that DAT helps explain jaundice cause.
Direct Antiglobulin Test (Newborn) NCLEX practice questions
Practice NCLEX-style clinical judgment focused on Direct Antiglobulin Test (Newborn) safety and nursing judgment. Use the case tabs (orders, results, assessment, nursing notes), then answer eight Next Gen–style items (including an ordered workflow step) and evaluate outcomes with the answer key.
Select a tab to view orders, results, assessment, and nursing note details for this case.
- Order: Newborn DAT — term nursery after positive cord Coombs
- Indication: 18-hour-old infant; DAT positive; evaluate hemolysis risk with rising bilirubin
- Timing: Born 39w0d; maternal type O Rh+; infant type A Rh+; cord DAT positive at delivery
- Related orders: Repeat DAT if protocol requires; serial TSB/TcB; CBC and reticulocyte count; blood bank notification
- Result: Cord DAT positive; peripheral confirmatory DAT positive; TSB 11.4 mg/dL at 18 h life
- Trend / prior value: Bilirubin rising from 8.9 mg/dL at 12 h to 11.4 mg/dL at 18 h; phototherapy threshold approaching
- Pending tests: Reticulocyte count pending; infant Hgb 13.8 g/dL
- Vital signs: T 36.9°C, HR 142/min, RR 46/min, SpO₂ 98% room air
- Symptoms: Jaundice to mid-chest; breastfeeding every 2–3 h; mild pallor noted
- Focused assessment: Alert, good tone; soft abdomen; not yet on phototherapy
- Preparation notes: Cord sample labeled and sent at delivery; parents ask if DAT means emergency transfusion
- Collection events: Cord blood to blood bank at 0912; peripheral heelstick 1630 for repeat DAT confirmation
- Teaching gaps / safety concerns: Positive DAT with rising bilirubin and pending reticulocytes; phototherapy threshold near; parent anxiety about transfusion
Answer key & rationale
Frequently Asked Questions
FAQ
When should a newborn DAT be ordered?
The 2022 AAP guideline recommends infant DAT and blood typing as soon as possible when the maternal antibody screen is positive or unknown. DAT is also part of jaundice and hemolysis workups when clinically indicated.
What does a positive newborn DAT mean?
It means antibodies are attached to the infant’s red blood cells, supporting antibody-mediated hemolysis — commonly related to ABO or Rh incompatibility. It increases hyperbilirubinemia risk and usually prompts closer bilirubin monitoring per prescriber plan.
Can DAT be positive without serious hemolysis?
Yes. AAP guidance infants may be DAT-positive after maternal Rh(D) immune globulin during pregnancy and may be managed differently than active isoimmune hemolysis — prescriber and blood bank interpret this context.
Does a negative DAT rule out all causes of jaundice?
No. A negative DAT lowers concern for antibody-mediated hemolysis but does not exclude non-immune hemolysis, breastfeeding-related jaundice, or other pathologic causes. Continue bilirubin screening and clinical monitoring per protocol.
Cord blood or heelstick — which is preferred?
When the maternal antibody screen is positive or unknown, cord blood at delivery allows earliest DAT and blood typing per AAP and blood-bank practice. If cord collection was missed, obtain a peripheral sample promptly rather than delaying.
What tests are often ordered with newborn DAT?
Clinicians commonly pair DAT with infant blood type, bilirubin, CBC, and reticulocyte count when hemolysis is suspected. Maternal antibody identification supports blood bank interpretation.
When should nurses escalate DAT-related results?
Escalate when DAT is positive with rapidly rising bilirubin, early jaundice, anemia signs, neurologic changes, or when a required DAT was not collected — according to facility policy.
References
References
-
Kemper AR; Newman TB; Slaughter JL; et al. Clinical Practice Guideline Revision: Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation. Pediatrics. 2022;150(3):e2022058859.https://doi.org/10.1542/peds.2022-058859
-
U.S. National Library of Medicine. Coombs test. MedlinePlus.https://medlineplus.gov/ency/article/003344.htm
-
U.S. National Library of Medicine. Hemolytic disease of the newborn. MedlinePlus.https://medlineplus.gov/ency/article/001298.htm
-
U.S. National Library of Medicine. Newborn jaundice. MedlinePlus.https://medlineplus.gov/ency/article/001559.htm
-
National Institute for Health and Care Excellence. Jaundice in newborn babies under 28 days. NICE guideline NG98.https://www.nice.org.uk/guidance/ng98
-
Stanford Medicine Newborn Nursery. The Coombs’ Test. Professional education.https://med.stanford.edu/newborns/professional-education/jaundice-and-phototherapy/the-coombs–test.html
-
Murray NA; Roberts IAG. Hemolytic disease of the newborn. Arch Dis Child Fetal Neonatal Ed. 2007;92(2):F83–F88.https://doi.org/10.1136/adc.2006.096370
-
Delaney M; Matthews DC. Hemolytic Disease of the Fetus and Newborn. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024.https://www.ncbi.nlm.nih.gov/books/NBK557423/
Editorial Standards & Medical Review
About the author: Sid A. Abdala Balal, RN, writes evidence-based nursing education focused on diagnostic safety, clinical interpretation, and bedside nursing judgment.
Medical review: This guide is reviewed by Dr. Adam Sayedi, MD, for clinical accuracy, diagnostic safety, and alignment with current standards for Direct Antiglobulin Test (Newborn).
Policies: Medical Review Process · Editorial Policy · Correction Policy